Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 12 de 12
Filter
Add more filters










Publication year range
1.
Trop Doct ; 54(1): 53-55, 2024 Jan.
Article in English | MEDLINE | ID: mdl-37899738

ABSTRACT

Acute toxic leukoencephalopathy and serotonin syndrome are rare neurological complications associated with various drugs and toxins, some of which overlap. However, the co-occurrence of these conditions is poorly documented. We present the case of a 14-year-old boy who suddenly developed altered consciousness and autonomic dysfunction after consuming excessive quantities of cough remedies containing dextromethorphan, chlorphenamine, dichlorobenzyl alcohol, and amylmetacreson. Magnetic resonance imaging of the brain revealed distinct white matter lesions. With supportive care, the patient rapidly improved, and the magnetic resonance imaging abnormalities disappeared. The swift resolution, typical magnetic resonance imaging findings, and a history of exposure to drugs affecting the central nervous system's serotonergic system suggested concurrent acute toxic leukoencephalopathy and serotonin syndrome. The components of cough medications can be hazardous in overdose due to their potential to enhance serotonin toxicity and cause direct or indirect central nervous system white matter damage. Early recognition and appropriate treatment are essential for recovery.


Subject(s)
Drug Overdose , Leukoencephalopathies , Serotonin Syndrome , Male , Humans , Adolescent , Serotonin Syndrome/chemically induced , Serotonin Syndrome/diagnosis , Serotonin Syndrome/pathology , Drug Overdose/complications , Drug Overdose/pathology , Leukoencephalopathies/diagnosis , Leukoencephalopathies/diagnostic imaging , Brain/diagnostic imaging , Brain/pathology , Magnetic Resonance Imaging , Cough
2.
Int J Mol Sci ; 22(9)2021 May 03.
Article in English | MEDLINE | ID: mdl-34063611

ABSTRACT

Serotonin (5-hydroxytryptamine, 5-HT) plays two important roles in humans-one central and the other peripheral-depending on the location of the 5-HT pools of on either side of the blood-brain barrier. In the central nervous system it acts as a neurotransmitter, controlling such brain functions as autonomic neural activity, stress response, body temperature, sleep, mood and appetite. This role is very important in intensive care, as in critically ill patients multiple serotoninergic agents like opioids, antiemetics and antidepressants are frequently used. High serotonin levels lead to altered mental status, deliria, rigidity and myoclonus, together recognized as serotonin syndrome. In its role as a peripheral hormone, serotonin is unique in controlling the functions of several organs. In the gastrointestinal tract it is important for regulating motor and secretory functions. Apart from intestinal motility, energy metabolism is regulated by both central and peripheral serotonin signaling. It also has fundamental effects on hemostasis, vascular tone, heart rate, respiratory drive, cell growth and immunity. Serotonin regulates almost all immune cells in response to inflammation, following the activation of platelets.


Subject(s)
Critical Illness , Inflammation/metabolism , Serotonin Syndrome/metabolism , Serotonin/metabolism , Blood-Brain Barrier/metabolism , Blood-Brain Barrier/pathology , Central Nervous System/metabolism , Central Nervous System/pathology , Delirium/metabolism , Delirium/pathology , Gastrointestinal Motility/physiology , Gastrointestinal Tract/metabolism , Gastrointestinal Tract/pathology , Humans , Inflammation/pathology , Myoclonus/metabolism , Myoclonus/pathology , Serotonin/biosynthesis , Serotonin Syndrome/pathology
3.
Int J Mol Sci ; 22(1)2020 Dec 26.
Article in English | MEDLINE | ID: mdl-33375373

ABSTRACT

L-5-hydroxytryptophan (5-HTP) is both a drug and a natural component of some dietary supplements. 5-HTP is produced from tryptophan by tryptophan hydroxylase (TPH), which is present in two isoforms (TPH1 and TPH2). Decarboxylation of 5-HTP yields serotonin (5-hydroxytryptamine, 5-HT) that is further transformed to melatonin (N-acetyl-5-methoxytryptamine). 5-HTP plays a major role both in neurologic and metabolic diseases and its synthesis from tryptophan represents the limiting step in serotonin and melatonin biosynthesis. In this review, after an look at the main natural sources of 5-HTP, the chemical analysis and synthesis, biosynthesis and microbial production of 5-HTP by molecular engineering will be described. The physiological effects of 5-HTP are discussed in both animal studies and human clinical trials. The physiological role of 5-HTP in the treatment of depression, anxiety, panic, sleep disorders, obesity, myoclonus and serotonin syndrome are also discussed. 5-HTP toxicity and the occurrence of toxic impurities present in tryptophan and 5-HTP preparations are also discussed.


Subject(s)
5-Hydroxytryptophan/analysis , 5-Hydroxytryptophan/pharmacology , Mental Disorders/drug therapy , Obesity/drug therapy , Serotonin Syndrome/drug therapy , Sleep Wake Disorders/drug therapy , Toxicological Phenomena , Animals , Biotechnology , Humans , Mental Disorders/metabolism , Mental Disorders/pathology , Obesity/metabolism , Obesity/pathology , Serotonin Syndrome/metabolism , Serotonin Syndrome/pathology , Sleep Wake Disorders/metabolism , Sleep Wake Disorders/pathology
4.
Cancer Control ; 24(5): 1073274817729070, 2017.
Article in English | MEDLINE | ID: mdl-28975823

ABSTRACT

Methylene blue is a widely used treatment for ifosfamide neurotoxicity. We present a case of severe encephalopathy complicating ifosfamide-based therapy for recurrent retroperitoneal leiomyosarcoma. After treatment with methylene blue, the patient experienced clinical decompensation and was diagnosed with serotonin syndrome based on a constellation of clinical findings. Withdrawal of methylene blue and other serotonergic medications led to clinical stabilization and ultimately neurological recovery. Our case highlights the challenge of diagnosing serotonin syndrome in the face of preexisting ifosfamide neurotoxicity, as there is significant clinical overlap between these 2 syndromes. Practitioners must remain vigilant of this potential life-threatening complication in this vulnerable population.


Subject(s)
Antineoplastic Agents, Alkylating/adverse effects , Ifosfamide/adverse effects , Neurotoxicity Syndromes/etiology , Serotonin Syndrome/etiology , Female , Humans , Methylene Blue , Middle Aged , Serotonin Syndrome/pathology
5.
Am J Trop Med Hyg ; 94(6): 1376-9, 2016 Jun 01.
Article in English | MEDLINE | ID: mdl-27001756

ABSTRACT

Human rabies is a fatal disease, transmitted by saliva of infected animals, and the diagnosis requires a high index of suspicion. Very few cases are reported annually in the United States. We present a case of human rabies without a clear exposure history that masqueraded as serotonin syndrome.


Subject(s)
Rabies virus/classification , Rabies/virology , Serotonin Syndrome/etiology , Animals , Diagnosis, Differential , Fatal Outcome , Genome, Viral , Humans , Male , Middle Aged , Rabies/pathology , Rabies virus/genetics , Serotonin Syndrome/pathology
7.
Neuropathology ; 31(3): 265-70, 2011 Jun.
Article in English | MEDLINE | ID: mdl-20880320

ABSTRACT

Serotonin syndrome is a potentially life-threatening reaction that occurs in patients using drugs that elevate the serotonin level in the body. Excess serotonergic activity in the CNS and peripheral serotonin receptors results in neuromuscular hyperactivity, mental changes and autonomic symptoms. Hyperthermia is a characteristic feature of the syndrome. We describe neuropathological findings from two cases of lethal serotonin syndrome, both patients presenting with hyperthermia and neuromuscular symptoms. One of the patients had been taking amitriptylin and mirtazapin and the other had used amitriptylin and citalopram. They died, respectively, 10 days and 2½ months after the onset of serotonin syndrome symptoms. Post-mortem examination of the brains showed subtotal loss of cerebellar Purkinje cells in both cases. In the case with shorter survival time, areas with partial loss of cerebellar granule cells were observed, whereas in the case with longer survival time general and extensive loss of granule cells was found. Cells in other areas of the brain known to be sensitive to hypoxic injury were not affected. Selective loss of Purkinje cells has previously been described in neuroleptic malignant syndrome and heatstroke, conditions that are characterized by hyperthermia. This suggests that hyperthermia may be a causative factor of brain damage in serotonin syndrome. This is the first report describing neuropathological findings in serotonin syndrome.


Subject(s)
Brain/pathology , Purkinje Cells/pathology , Pyramidal Cells/pathology , Serotonin Syndrome/pathology , Cerebellum/pathology , Cerebral Cortex/pathology , Fatal Outcome , Female , Hippocampus/pathology , Humans , Male , Middle Aged
8.
Clin Neuropharmacol ; 32(5): 299-300, 2009.
Article in English | MEDLINE | ID: mdl-19820435

ABSTRACT

We report the case of a 24-year-old female patient who initially developed a neuroleptic malignant syndrome after haloperidol exposure and experienced 6 years later a serotonin syndrome after repeated fluoxetine exposure. The patient did not respond to symptomatic treatment and died in this latter episode. At necropsy, no gross or microscopic changes were seen with conventional histological stains, and immunohistochemical stains were negative. This is the first clinicopathologic case of a patient who experienced both neuroleptic malignant and serotonin syndromes. We speculate that this case argue in favor that both syndromes share some fundamental pathogenetic mechanisms.


Subject(s)
Neuroleptic Malignant Syndrome/complications , Neuroleptic Malignant Syndrome/pathology , Serotonin Syndrome/complications , Serotonin Syndrome/pathology , Fatal Outcome , Female , Fluoxetine/adverse effects , Haloperidol/adverse effects , Humans , Serotonin Syndrome/chemically induced , Young Adult
9.
Eur J Pharmacol ; 512(2-3): 173-9, 2005 Apr 11.
Article in English | MEDLINE | ID: mdl-15840402

ABSTRACT

Serotonin syndrome commonly follows irreversible monoamine oxidase (MAO)-inhibition and subsequent serotonin (5-HT) substrate (in rats with fore paw treading, hind limbs abduction, wet dog shake, hypothermia followed by hyperthermia). A stable gastric pentadecapeptide BPC 157 with very safe profile (inflammatory bowel disease clinical phase II, PL-10, PLD-116, PL-14736, Pliva) reduced the duration of immobility to a greater extent than imipramine, and, given peripherally, has region specific influence on brain 5-HT synthesis (alpha-[14C]methyl-L-tryptophan autoradiographic measurements) in rats, different from any other serotonergic drug. Thereby, we investigate this peptide (10 microg, 10 ng, 10 pg/kg i.p.) in (i) full serotonin syndrome in rat combining pargyline (irreversible MAO-inhibition; 75 mg/kg i.p.) and subsequent L-tryptophan (5-HT precursor; 100 mg/kg i.p.; BPC 157 as a co-treatment), or (ii, iii) using pargyline or L-tryptophan given separately, as a serotonin-substrate with (ii) pargyline (BPC 157 as a 15-min posttreatment) or as a potential serotonin syndrome inductor with (iii) L-tryptophan (BPC 157 as a 15 min-pretreatment). In all experiments, gastric pentadecapeptide BPC 157 contrasts with serotonin-syndrome either (i) presentation (i.e., particularly counteracted) or (ii) initiation (i.e., neither a serotonin substrate (counteraction of pargyline), nor an inductor for serotonin syndrome (no influence on L-tryptophan challenge)). Indicatively, severe serotonin syndrome in pargyline + L-tryptophan rats is considerably inhibited even by lower pentadecapeptide BPC 157 doses regimens (particularly disturbances such as hyperthermia and wet dog shake thought to be related to stimulation of 5-HT2A receptors), while the highest pentadecapeptide dose counteracts mild disturbances present in pargyline rats (mild hypothermia, feeble hind limbs abduction). Thereby, in severe serotonin syndrome, gastric pentadecapeptide BPC 157 (alone, no behavioral or temperature effect) has a beneficial activity, which is likely, particular, and mostly related to a rather specific counteraction of 5-HT2A receptors phenomena.


Subject(s)
Anti-Ulcer Agents/pharmacology , Peptide Fragments/pharmacology , Proteins/pharmacology , Serotonin Syndrome/prevention & control , Animals , Anti-Ulcer Agents/therapeutic use , Antidepressive Agents, Second-Generation/pharmacology , Antidepressive Agents, Second-Generation/therapeutic use , Behavior, Animal/drug effects , Body Temperature/drug effects , Dose-Response Relationship, Drug , Drug Therapy, Combination , Male , Monoamine Oxidase Inhibitors/pharmacology , Monoamine Oxidase Inhibitors/therapeutic use , Pargyline/pharmacology , Pargyline/therapeutic use , Peptide Fragments/therapeutic use , Proteins/therapeutic use , Rats , Rats, Wistar , Serotonin Syndrome/pathology , Time Factors , Treatment Outcome , Tryptophan/pharmacology , Tryptophan/therapeutic use
10.
Clin Toxicol (Phila) ; 43(1): 39-45, 2005.
Article in English | MEDLINE | ID: mdl-15732445

ABSTRACT

The symptoms and signs of carisoprodol intoxications do not resemble those caused by its metabolite meprobamate. Meprobamate most probably produces its effects through the GABAergic neurotransmitter system. The signs and symptoms of carisoprodol intoxications, however, are not easily explained by interaction with this neurotransmitter system. In the present study, four cases of carisoprodol intoxications are presented with emphasis on the presence of serotonergic signs and symptoms. All four cases fulfilled three different sets of criteria for the diagnosis of serotonin syndrome. These findings could indicate that an increased serotonin level in the central nervous system could explain some of the symptoms and signs of carisoprodol intoxications. This may have implications for the clinical evaluation and treatment of such intoxications. Since few laboratories routinely screen for carisoprodol it is important to keep this drug in mind when encountering intoxications displaying serotonergic symptoms.


Subject(s)
Carisoprodol/adverse effects , Muscle Relaxants, Central/adverse effects , Serotonin Syndrome/diagnosis , Adult , Carisoprodol/blood , Diagnosis, Differential , Drug Overdose/blood , Drug Overdose/diagnosis , Drug Overdose/etiology , Female , Humans , Muscle Relaxants, Central/blood , Serotonin Syndrome/blood , Serotonin Syndrome/chemically induced , Serotonin Syndrome/pathology
11.
Article in English | MEDLINE | ID: mdl-15276688

ABSTRACT

Serotonin (5-HT) syndrome is a potentially fatal condition associated with various combinations of serotonergic drugs. The present study was undertaken to demonstrate that nervous systems other than the 5-HT system also participate in the pathophysiology of 5-HT syndrome. Concentrations of 5-HT, dopamine (DA) and glutamate in the hypothalamus were measured in two different 5-HT syndrome animal models using a microdialysis technique. The first model was induced by tranylcypromine, a nonselective monoamine oxidase (MAO) inhibitor (3.5 mg/kg) and fluoxetine, a selective serotonin reuptake inhibitor (SSRI) (10 mg/kg). The second model was induced by clorgyline, an MAO-A inhibitor (1.2 mg/kg) and 5-hydroxy-L-tryptophan, a precursor of 5-HT (5-HTP) (80 mg/kg). In the first model, the levels of 5-HT and DA increased by 40-fold and 44-fold, respectively, compared with the preadministration levels. In the second model, the concentrations of 5-HT increased by up to 140-fold, whereas DA levels increased by only 10-fold, of the preadministration levels. Although the level of glutamate in the second model barely changed, a delayed increase in the glutamate level was observed in the first model. These findings suggest that not only hyperactivity of the 5-HT system, but also hyperactivity of the DA system, are present in 5-HT syndrome, and that the glutamatergic system is influenced in some 5-HT syndrome cases in which the DA concentration markedly increases.


Subject(s)
Antidepressive Agents/toxicity , Dopamine/metabolism , Extracellular Fluid/metabolism , Fluoxetine/toxicity , Glutamic Acid/metabolism , Hypothalamus/metabolism , Selective Serotonin Reuptake Inhibitors/toxicity , Serotonin Syndrome/chemically induced , Serotonin Syndrome/metabolism , Serotonin/metabolism , Tranylcypromine/toxicity , Animals , Biogenic Monoamines/metabolism , Body Temperature/drug effects , Fever/chemically induced , Fever/physiopathology , Hypothalamus/pathology , Male , Microdialysis , Rats , Rats, Wistar , Serotonin Syndrome/pathology
12.
J Anal Toxicol ; 25(2): 147-51, 2001 Mar.
Article in English | MEDLINE | ID: mdl-11300508

ABSTRACT

We present a case involving a fatality due to the combined ingestion of two different types of antidepressants. A 41-year-old Caucasian male, with a history of depression and suicide attempts, was found deceased at home. Multiple containers of medication, the MAO-inhibitor moclobemide (Aurorix), the SSRI citalopram (Cipramil), and the benzodiazepine lormetazepam (Noctamid) as active substance, as well as a bottle of whiskey were present at the scene. The autopsy findings were unremarkable, but systematic toxicological analysis (EMIT, radioimmunoassay, high-performance liquid chromatography-diode-array detection [HPLC-DAD], gas chromatography-nitrogen-phosphorus detection, and gas chromatography-mass spectrometry) revealed the following: ethanol (0.23 g/L blood, 0.67 g/L urine), lormetazepam (1.65 microg/mL urine), cotinine (0.63 microg/mL blood, 5.08 microg/mL urine), caffeine (1.20 microg/mL urine), moclobemide (and metabolites), and citalopram (and metabolite). There upon, we developed a new liquid chromatographic separation with optimized DAD, preceded by an automated solid-phase extraction, for the quantitation of the previously mentioned antidepressive drugs. The results obtained for blood and urine, respectively, were as follows: Ro 12-5637 (moclobemide N'-oxide) not detected and 424 microg/mL; Ro 12-8095 (3-keto-moclobemide) 2.26 microg/mL and 49.7 microg/mL; moclobemide 5.62 microg/mL and 204 microg/mL; desmethylcitalopram 0.42 microg/mL and 1.22 microg/mL; and citalopram 4.47 microg/mL and 19.7 microg/mL. The cause of death was attributed to the synergistic toxicity of moclobemide and citalopram, both antidepressants, which, by intentional or accidental combined ingestion, can produce a potentially lethal hyperserotoninergic state. Based on the history of the case and pharmacology of the drugs involved, the forensic pathologists ruled that the cause of death was multiple drug intoxication, resulting in a fatal "serotonin syndrome," and that the manner of death was suicide.


Subject(s)
Antidepressive Agents/poisoning , Citalopram/poisoning , Moclobemide/poisoning , Serotonin Syndrome/chemically induced , Suicide , Adult , Antidepressive Agents/metabolism , Chromatography, High Pressure Liquid , Citalopram/metabolism , Drug Combinations , Enzyme Multiplied Immunoassay Technique , Fatal Outcome , Gas Chromatography-Mass Spectrometry , Humans , Male , Moclobemide/metabolism , Radioimmunoassay , Serotonin Syndrome/pathology
SELECTION OF CITATIONS
SEARCH DETAIL
...